Literature DB >> 20494220

Potential mechanisms for HPV vaccine-induced long-term protection.

Margaret Stanley1.   

Abstract

Human papillomaviruses (HPVs) are small double-stranded DNA viruses that infect the skin and internal squamous mucosae. These viruses were once considered to be the causal agent only of skin or genital warts--lesions of trivial significance. It turns out, however, that HPVs belong to a large virus family that includes individual types that are major global carcinogens causing an estimated 4-5% of all cancers, mainly, but not exclusively, in the anogenital tract of men and women [1]. Even the "trivial" warts, particularly those occurring on the anogenital skin or in the larynx, result in substantial morbidity and are a major health-economic burden [2]. Vaccination is the most effective means that we have of preventing infectious disease, and during the past decade the development of prophylactic vaccines that target infection with the major pathogenic HPVs gives the possibility of controlling these infections and their disease sequelae. Copyright (c) 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494220     DOI: 10.1016/j.ygyno.2010.04.002

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  20 in total

1.  Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.

Authors:  Douglas M Herrin; Emily E Coates; Pamela J Costner; Troy J Kemp; Martha C Nason; Kapil K Saharia; Yuanji Pan; Uzma N Sarwar; Lasonji Holman; Galina Yamshchikov; Richard A Koup; Yuk Ying S Pang; Robert A Seder; John T Schiller; Barney S Graham; Ligia A Pinto; Julie E Ledgerwood
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.

Authors:  Mari Nygård; Alfred Saah; Christian Munk; Laufey Tryggvadottir; Espen Enerly; Maria Hortlund; Lara G Sigurdardottir; Scott Vuocolo; Susanne K Kjaer; Joakim Dillner
Journal:  Clin Vaccine Immunol       Date:  2015-06-17

3.  The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.

Authors:  Vladimir Gilca; Chantal Sauvageau; Nicole Boulianne; Gatson De Serres; Mel Crajden; Manale Ouakki; Andrea Trevisan; Marc Dionne
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Innovations in lymph node targeting nanocarriers.

Authors:  Jihoon Kim; Paul A Archer; Susan N Thomas
Journal:  Semin Immunol       Date:  2021-11-24       Impact factor: 11.130

5.  Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial.

Authors:  Sabrina H Tsang; Joshua N Sampson; John Schussler; Carolina Porras; Sarah Wagner; Joseph Boland; Bernal Cortes; Douglas R Lowy; John T Schiller; Mark Schiffman; Troy J Kemp; Ana Cecilia Rodriguez; Wim Quint; Mitchell H Gail; Ligia A Pinto; Paula Gonzalez; Allan Hildesheim; Aimée R Kreimer; Rolando Herrero
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

6.  Primary prevention and vaccination for penile cancer.

Authors:  Majid Shabbir; Ravi Barod; Paul K Hegarty; Suks Minhas
Journal:  Ther Adv Urol       Date:  2013-06

7.  A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.

Authors:  Eve Draper; Sara L Bissett; Rebecca Howell-Jones; Pauline Waight; Kate Soldan; Mark Jit; Nicholas Andrews; Elizabeth Miller; Simon Beddows
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

8.  Global challenges of implementing human papillomavirus vaccines.

Authors:  Janice E Graham; Amrita Mishra
Journal:  Int J Equity Health       Date:  2011-06-30

9.  Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.

Authors:  Eve Draper; Sara L Bissett; Rebecca Howell-Jones; Debbie Edwards; Graham Munslow; Kate Soldan; Simon Beddows
Journal:  Vaccine       Date:  2011-09-21       Impact factor: 3.641

10.  Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.

Authors:  Sara L Bissett; Eve Draper; Richard E Myers; Anna Godi; Simon Beddows
Journal:  Vaccine       Date:  2014-01-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.